32 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- BGOG-cx1/ENGOT-cx1 Randomized double-blind phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma Uterus phase 2 Closed Second line
- C101 Open, non-controlled, multicenter, first-in-human study for the evaluation of the safety, pharmacokinetics and preliminary antitumor activity of GM102 in patients with advanced pretreated gynecological cancer Multiple phase 1 Closed Any line, RECIST 1.1
- CA209358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors Multiple phase 1/2 Closed ECOG 0 or 1
- CHIPOR CHIPOR : randomized phase III study evaluating hypertermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse Ovary phase 3 Closed Status WHO < 2. Adjuvant
- EMBER A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Therapies for Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers Multiple phase 1/1b Closed
- ENGOT-cx12 - SGNTV-003 A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator's Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer Uterus phase 3 Closed
- EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis
- EORTC 55092 Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma Multiple phase 1/2 Closed Platinium-refractory
- EPIK-O A Phase III, multi-center, randomized (1:1), open-label, activecontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O / CBYL719K12301) Ovary phase 3 Closed
- EVICTION A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer Multiple phase 1 Open Relasped/refractory patient
- I4D-MC-JTJN A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Ovary phase 2 Closed Platinium resistant
- I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy